The Medtronic center will facilitate surgeon collaboration and AI-powered decision support. At Virtuoso Surgical, a robotic approach to bladder lesion removal is expected to improve precision.
In this discussion, our guests explore how modern data lake architectures, built on AWS, can help your organization adopt FAIR data principles—Findable, Accessible, Interoperable, and Reusable—to unlock the full potential of your scientific data.
Webinar: Data Lakes & FAIR Principles: Making Scientific Data Accessible and Actionable Read More »
La creciente dependencia de la tecnología En las últimas décadas, el uso de sistemas digitales se ha convertido en el eje de las operaciones empresariales. La digitalización ha traído consigo eficiencia, rapidez y nuevas oportunidades de negocio. Sin embar …
Talent acquisition leaders at leading pharma and biotech organizations are leveraging technologies, including automation, to develop internal talent marketplaces and systems that support upskilling and reskilling their workforce. BioSpace spoke to leaders at Pfizer and Bayer about their evolving approach to resourcing.
Talent Acquisition Leaders Reframe Recruiting, Focus On Internal Mobility Read More »
It’s an opportunity for Privia to further increase its shared savings in Medicare’s largest value-based program, while enticing Evolent Care Partners’ affiliated physicians onto its technology and services platform.
Privia acquires Evolent’s value-based primary care unit for $100M Read More »
Consolidation with health systems can lead to higher prices, alongside a decrease or no change in care quality, according to a review from the Government Accountability Office.
Physician practice acquisitions on the rise: GAO Read More »
Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential to ease hyperphagia in the rare neurological condition.
Acadia Scraps Prader-Willi Drug After Late-Stage Failure Read More »
Cardiosense’s switch to a leader with experience scaling healthtech companies comes as it works to build on the recent 510(k) clearance of CardioTag.
If approved, uniQure’s gene therapy AMT-130—which slowed disease progression by 75%—would be the first genetic treatment for Huntington’s disease. A BLA submission is planned for the first quarter of 2026.
UniQure ‘Exceeds Expectations’ in Much-Anticipated 3-Year Huntington’s Readout Read More »
Sanofi Ventures, which now has $1.4 billion in total assets, will focus its investment efforts on early players working in immunology, rare diseases, neurology and vaccines.
Sanofi Fattens Venture Unit With $625M Infusion for Rare Disease, Neuro Innovation Read More »
